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Introduction: Heart failure (HF) is a complex clinical syndrome associated with high mortality, mor-
bidity, and healthcare expenditures.1,2 We sought to determine temporal trends concerning baseline 
characteristics and treatment modalities of patients enrolled at our Center during two periods: 2008-
2012 and 2018-2019 for which data were available. 
Patients and Methods: Patients admitted with the chief diagnosis of HF were stratified into two groups 
for the statistical analysis. The historic cohort comprised patients admitted during the period 2008-
2012 (N=356) while the contemporary cohort (2018-2019) consisted of 108 patients. 
Results: Patients in the contemporary cohort were younger, had a significantly higher prevalence of 
non-ischemic cardiomyopathy, diabetes mellitus, more preserved renal function, higher hemoglobin, 
higher uric acid, and lower potassium levels compared to the historic cohort. On the other hand, distri-
bution of sex, blood pressure at admission, the prevalence of atrial fibrillation, NYHA functional class, 
left ventricular ejection fraction and left end-diastolic diameters were similar in both groups (Table 1). 
TABLE 1. Baseline characteristics of patients in historic (2008-2012) and contemporary (2018-2019) 
heart failure cohorts treated at the University Hospital Centre Split.







Female sex 51.1% 49.1% 0.709
Age, years 74.2 ± 9.9 70.2 ± 10.9 <0.001*
Ischemic cardiomyopathy 76.4% 49.1% <0.001*
Atrial fibrillation 52.0% 54.6% 0.627
Diabetes mellitus 27.5% 44.4% <0.001*
NYHA functional class 3.07 ± 0.7 3.06 ± 0.6 0.875
LVEF, % 42.3 ± 9.4 43.8 ± 17.0 0.213
LVEDd, mm 64 ± 81 59 ± 10 0.499
Urea, mmol/L 9.3 ± 7.7 10.7 ± 5.6 0.084
Creatinine, μmol/L 142 ± 95 117 ± 59 0.009*
eGFR, mL/min./1.73 m2 49 ± 23 58 ± 25 <0.001*
Uric acid, mmol/L 486 ± 172 535 ± 166 <0.001*
Hemoglobin, g/L 126 ± 20 134 ± 20 <0.001*
Sodium, mmol/L 138 ± 4.4 138 ± 3.7 0.762
Potassium, mmol/L 4.5 ± 0.8 4.1 ± 0.5 <0.001*
Systolic blood pressure, mmHg 137 ± 28 137 ± 29 0.145
Diastolic blood pressure, mmHg 81 ± 15 81 ± 13 0.204
LVEDd-left ventricular end-diastolic diameter; LVEF-left ventricular ejection fraction; NYHA-New York Heart Association; eGFR-esti-
mated glomerular filtration rate
*denotes statistically significant result at p<0.05 level (Chi-square analysis or Student t-test were used for comparisons between two groups)
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As shown in Figure 1A, we observed a significant decline in the prevalence of HF with midrange ejection fraction in a contempo-
rary cohort compared to a historic one (p<0.001) along with a significant increase in the prevalence of HF with preserved ejection 
fraction and HF with reduced ejection fraction (p<0.001). Regarding treatment modalities, acetylsalicylic acid use significantly de-
clined while the use of oral anticoagulants significantly increased among the contemporary cohort compared to the historic one. 
Likewise, the use of life-prolonging therapy such as beta-blockers increased by about 45%, and ACE-inhibitors or ARBs by about 11% 
accompanied by the slight decrease in the use of loop diuretics (Figure 1B). 
Conclusions: After the approximately 10-year timespan, we observed several changes in baseline characteristics of HF patients 
treated at our center. The most prominent change is the highest relative growth in the prevalence of HF with preserved ejection 
fraction. Likewise, the proportional use of life-prolonging pharmacotherapies and anticoagulation coverage (nowadays mostly 
direct oral anticoagulants) significantly improved over time.
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FiGure 1. A) Change in heart failure clinical phenotypes over time in two compared cohorts; B) Trends in pharmacotherapy use over 
time in two compared cohorts.
ACE-Angiotensin-converting enzyme; ARB-angiotensin receptor blocker; HFmrEF-heart failure with midrange ejection fraction; HFpEF-heart failure with 
preserved ejection fraction; HFrEF-heart failure with reduced ejection fraction
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